Category: Vaccine

Page 131«..1020..130131132133..140150..»

There’s ‘little to no interest’ in latest COVID vaccine, and health leaders worry about long-term implications – The Kansas City Beacon

December 13, 2023

Alexandria Thompsons job is to convince the most vulnerable people in her community to get vaccinated for the flu and COVID-19.

She can offer education, transportation and up to $50 in gift cards to entice people to get the shots. But, she says, often that is not enough.

I just tend to lead with the flu shot, and then Ill say COVID right after, said Thompson, the lead canvasser for G.O.T.V. (Get Out the Vaccines), an initiative of the Kansas City advocacy organization Communities Creating Opportunity. Many times, people say no to the COVID shot and, a lot of times, people say yes to the flu shot.

Going on four years since the SARS-CoV-2 virus devastated lives and economies worldwide, health care providers and public health advocates say a growing number of people seem to have lost sight of just how dangerous the virus can be. Perhaps as a result, most people arent rolling up their sleeves for the latest vaccine.

There is little to no interest in it, said Carole Thomas, vice president of clinical operations for KC Care Health Center.

Nationally, just 16% of adults and 7% of children had received the latest version of the shot by the start of December, said the U.S. Centers for Disease Control and Prevention. The Kansas City Health Department administered 1,420 doses between September and early December, fewer than the number given in just one week during the height of the pandemic.

People tend to treat COVID as a cold or just another respiratory illness thats going to be here to stay, said Betty Criss, public health nursing supervisor with the Wyandotte County Health Department. But we still need to take measures to prevent the spread of COVID. We still need to take measures to protect our own health and our own familys health.

When Criss sees available COVID vaccine appointments going unscheduled week after week, she knows a lot of people have forgotten that COVID can still kill.

Although COVID cases are a fraction of what they were three and four years ago, people still end up in the hospital with the disease. On Dec. 8, for example, the University of Kansas Health System had 22 patients hospitalized for the virus. University Health had 13. And St. Lukes Health System had 38.

Besides apathy, health providers said, people refuse the vaccine for political reasons, because of general distrust in the health system or because of blatantly inaccurate information they stumble across from the internet and other media.

Because COVID happened and caused us to be socially isolated from each other a lot of people went down these rabbit holes, Thomas said. A lot of people have very, very strong feelings about it.

Health experts warn that ongoing vaccine avoidance could add up to tragic outcomes for vulnerable patients and, potentially, lead to another devastating public health crisis.

Besides COVID, the country is vulnerable to outbreaks from illnesses, like flu, hepatitis B, pneumococcal disease and measles because too few Americans get vaccinated, said Cecelia Thomas, a senior government relations manager at Trust for Americas Health, a public health policy research and advocacy organization in Washington.

Its not if there will be another pandemic, she said, but when.

During the pandemic, Congress spent heavily and quickly to shore up the countrys ability to make and distribute vaccines and to sell people on the science that supports widespread vaccinations. But that emergency funding is running out.

Thomas said federal spending on immunization efforts has fallen short for a decade and remains precarious. Last year, the federal government doled out $325 million to states, cities and territories, including $5.9 million to Missouri and $2.8 million to Kansas.

A U.S. Senate committee has called for spending $682 million next year, including the money sent to local government and tax dollars that stay with the CDC. The House isnt expected to act on the funding until January.

Thomas contends the country needs to spend closer to $1 billion. Its a snowball, she said. Health agencies dont have funding, so they cant hire people. If they dont hire people, they cant put out education. They cant administer the vaccine.

Ultimately, she said, It all leads down to another big spread of a deadly virus.

Thats exactly what local hospitals want to avoid. Health care administrators say people need to get the message that COVID while much less deadly today can still kill and lead to long-term health issues. The National Center for Health Statistics estimates that by the end of 2022, 6.9 percent of Americans had suffered from long COVID, defined as symptoms that last three or more months after an initial infection.

Complacency is great until you get really sick, said Steven W. Stites, a pulmonologist and chief medical officer at the University of Kansas Health System.

Its hard to know exactly how the virus will hit individual patients, he said. If its been a long time since you were exposed or vaccinated, your body may not recognize the changed virus and have a harder time fighting it off.

The more changes (the virus) has undergone since the last time you had COVID will really help dictate how fast your body can respond to it, Stites said. Its like seeing some old person you havent seen for 20 years. They look so darn different you cant recognize them.

Staying up to date on the vaccine, even if youre healthy, will help your body win the fight. And, importantly, itll help keep the virus from spreading to more vulnerable people.

The people who are young and healthy, they may get it and they may do OK, said Mark Steele, executive chief clinical officer with University Health. But they may get it and they may give it to somebody whos not young and healthy.

Thats why Thompson of Communities Creating Opportunity will continue to fight rumors and convince people to get the latest shot.

Since September, the G.O.T.V. campaign has led to about 200 people getting the shot.

People who are 65 or older or have a disability can qualify for two $25 Walmart gift cards one for each shot they receive. In addition to getting the vaccines, participants have to fill out a survey to receive the gift cards, which are funded by the Center for Popular Democracy through a grant from the Department of Health and Human Services.

The program has funding to reach 800 to 1,000 participants in the Kansas City area.

Thompson said its particularly important to make progress vaccinating Black people, a group that was hit extremely hard in the pandemic.

Theres a lot of distrust between the medical care system and the Black community because of things that have happened in the past with medicine, Thompson said. She pointed to the Tuskegee experiment, a federally funded effort that studied 400 Black men with untreated syphilis for 40 years without giving them any information about the study.

Thats one reason accurate information is key to the work Thompson is doing.

We try our hardest to spread education because we want people to still get the shot next year, she said. We dont want them to just do it one year because theyre getting incentivized.

Read more from the original source:

There's 'little to no interest' in latest COVID vaccine, and health leaders worry about long-term implications - The Kansas City Beacon

Impact of COVID-19 infections and vaccines on preterm birth – National Institutes of Health (.gov)

December 13, 2023

At a Glance

A healthy human pregnancy lasts for about 40 weeks. Preterm birthbirth occurring before 37 weeksincreases the risk of infant death andmany lasting health problems.

Infection with SARS-CoV-2 (the virus that causes COVID-19) during the third trimester of pregnancy has been linked with an increased risk of preterm birth. Vaccines against SARS-CoV-2 have been shown to be safe and effective during pregnancy. However, whether they reduce the risk of preterm birth hasnt been clear.

In a new study funded in part by NIH, Dr. Florencia Torche from Stanford University and Dr. Jenna Nobles from the University of Wisconsin-Madison looked more closely at this question. They examined births in California hospitals between 2014 and 2023. Beginning in June 2020, the state tracked COVID testing on mothers upon admission. This provided a highly accurate estimate of infections during labor and delivery among hospitals with universal testing. Results were published in the December 5, 2023, issue of Proceedings of the National Academy of Sciences.

The researchers analyzed siblings to examine the effects of COVID-19 infections. This approach accounts for other factors that might affect the risk of preterm birth, such as poverty, race and ethnicity, and personal risk factors. The analysis showed that COVID-19 infection raised the risk of preterm birth from 7.1% to 8.3% from July 2020 to February 2023. This increase in risk is similar to that seen from a massive environmental exposure, such as three weeks of exposure to high-intensity wildfire smoke.

The largest effect of maternal COVID-19 infection on preterm birth was in 2020, with the preterm birth rate rising by 5.4% between July and November 2020. COVID-19 infection then increased the probability of preterm birth by around 2-4% during 2021, which saw waves of infections caused by different variants. During 2022, the impact of COVID-19 infection on preterm birthdisappeared.

To tease out the effect of vaccination, the researchers compared the impact of COVID-19 infection on preterm births between areas with the fastest vaccine uptake and those with the slowest. Zip codes with the fastest uptake had an 86% vaccination rate by March 2022. Those with the lowest rates reached 51% during the same time period. Until May 2021, the impact of COVID-19 infection on preterm birth rates was similar between areas. They then dropped sharply in high-vaccination areas, while staying high in low-vaccination areas until almost a year later. This strongly suggests that vaccination accounted for the difference in the rate of preterm births.

By the end of 2022, the impact of COVID-19 on preterm births had faded, despite an increase in infections caused by the Omicron variant. Vaccines had become widely available as well as effective therapies for COVID-19. New variants had emerged, and more of the population had acquired immunity to SARS-CoV-2.

As SARS-CoV-2 continues to mutate, updated booster shots will likely be needed to keep immunity high. Currently, booster uptake in pregnant individuals lags behind that of the rest of the population.

We already know there is very little evidence of adverse effects of vaccination on fetal development. The results here are compelling evidence that what will actually harm the fetus is not getting vaccinated, Nobles says. By increasing immunity faster, early vaccination uptake likely prevented thousands of preterm births in the U.S.

by Sharon Reynolds

Funding:NIHs Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Science Foundation.

Read the original post:

Impact of COVID-19 infections and vaccines on preterm birth - National Institutes of Health (.gov)

NHS vaccinations to be booked online in drive to increase uptake – BBC.com

December 13, 2023

2 hours ago

The plans aim to build on the success of the Covid vaccination programme, NHS England said

People in England will be able to book all their routine vaccinations on a mobile app or online within the next three years under NHS plans.

Health bosses want to build on the Covid vaccination programme in order to increase uptake of other potentially life-saving jabs.

Currently, jabs other than for flu and Covid must be booked over the phone.

NHS England also wants to increase community outreach in areas where the take-up of some jabs is low.

Under the plans, 16 jabs for vaccine-preventable diseases, including measles, mumps and rubella (MMR) and human papillomavirus (HPV), will be available to book online by the end of 2026.

The new booking system will generate vaccination invitations and appointment alerts.

It will also allow people to view their, and their children's, medical and vaccination records online.

Health Minister Maria Caulfield said: "To ensure as many people get vaccinated as possible, we need to make sure the programme fits around people's lives."

She said the plans also aimed "to reach people who would not typically come forward for their jabs".

"Living Well" buses will increasingly be sent into communities to provide jabs and health checks, under the plans

Greg Fell, president of the Association of Directors of Public Health, said vaccinations were one of the biggest defences against disease and ill-health, so it was vital that everyone eligible could access them.

"We saw during the Covid-19 pandemic that this is not always as straightforward as sending out an invitation, and also saw the devastating impact low vaccination rates can have on communities," he said.

Under the strategy, health professionals will undertake community work to improve "vaccine confidence", following a drop in uptake of some vaccinations - including the MMR jab - in some areas.

Additionally, vaccines will be offered more widely in non-NHS settings, such as sports centres, shopping centres and people's homes, NHS England said.

Prof Dame Jenny Harries, chief executive of the UK Health Security Agency, welcomed the plans. She said: "The link between uptake rates and vaccine confidence and accessibility is critical and I welcome this renewed focus by NHS England on innovative delivery approaches responding to local need."

Around nine in 10 children in England have received their pre-school immunisations, with flu vaccination rates among the highest in the world, NHS England said. However, this strategy is aimed at increasing rates still further.

Currently, more then 33 million people have signed up to the NHS app.

This autumn so far, 5.1 million NHS flu and Covid vaccines been booked in total online - 1.2 million via the app.

Visit link:

NHS vaccinations to be booked online in drive to increase uptake - BBC.com

Novavax’s Updated COVID-19 Vaccine Now Available as Only Option in Poland – Dec 11, 2023 – Novavax Investor Relations

December 13, 2023

FOR MEDICAL AUDIENCES ONLY

Novavaxs updated protein-based non-mRNA COVID-19 vaccine is now available for use in Poland for the prevention of COVID-19 in individuals aged 12 and older. Doses have been distributed by the appropriate Polish authorities and made available for this season's vaccination campaign. The Novavax vaccine is currently the only updated COVID-19 vaccine option available in Poland.

We are pleased that our updated vaccine is available in time for the upcoming Christmas and winter holiday season. We are honored to support both the Polish government and the countrys healthcare workers to help protect Polish citizens and their loved ones against COVID-19. Starting today, individuals across the country can receive an updated vaccine.

Non-clinical datashowed that Novavax's updated COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated that Novavax's vaccine induced neutralizing antibody responses to subvariants BA.2.86, EG.5.1, FL.1.5.1 and XBB.1.16.6 as well as CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6. These data indicate Novavax's vaccine can stimulate both arms of the immune system and may induce a broad response against currently circulating variants.1,2

Forward-Looking Statements

Statements herein relating to the future of Novavax, its operating plans and prospects, including the availability of its updated XBB version of its Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) in Poland and the timing of delivery and distribution of its vaccine are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; manufacturing, distribution or export delays or challenges; Novavax's exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the impact of any delays or disruptions in their operations on the delivery of customer orders; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at http://www.sec.gov and http://www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

References:

See the rest here:

Novavax's Updated COVID-19 Vaccine Now Available as Only Option in Poland - Dec 11, 2023 - Novavax Investor Relations

Vaccine Maker Adar Poonawalla To Buy Mansion In London’s Mayfair. It Costs… – NDTV

December 13, 2023

Adar Poonawalla is the son of Cyrus Poonawalla, the founder of the Serum Institute of India.

Billionaire CEO of Serum Institute of India, Adar Poonawalla, has sealed a deal to buy a multi-million-pound mansion in London's Mayfair, the Financial Times reported. The sale of the 25,000-square-foot mansion located near Hyde Park in London will make it the most expensive home sale of the year.

Aberconway House, located near London's famous Hyde Park, is a vast 1920s home and will be reportedly sold for at least 138 million pounds (approximately Rs 1,444.4 crore), the FT report said. Dominika Kulczyk, the daughter of the late Polish businessman Jan Kulczyk, will reportedly sell the property to Mr Poonawalla.

As per reports, the property will be acquired by Serum Life Sciences, a British subsidiary of the Poonawalla family's Serum Institute of India.

The price tag makes Aberconway House the second-most expensive home ever sold in London and the biggest deal of the year, according to luxury property agents.

New home sales in London are declining and experts believe this shows London's luxury property market is insulated from the impact of higher borrowing costs which have slowed the UK housing market this year.

A person close to Serum Life Sciences told FT that the Poonawalla family had "no plans" to move to the UK permanently, but that "the house will serve as a base for the company and family when they are in the UK".

The Serum Institute of India is credited for its role during the Covid pandemic. The vaccine manufacturer produced the Serum Covishield vaccine developed by AstraZeneca and Oxford University, which was widely used to vaccinate millions of people in India.

Adar Poonawalla is the son of Cyrus Poonawalla, the founder of the Serum Institute of India.

Adar Poonawalla joined the Serum Institute of India in 2001 and became the CEO of Serum Institute with complete control of the day-to-day operations of the company in 2011.

Here is the original post:

Vaccine Maker Adar Poonawalla To Buy Mansion In London's Mayfair. It Costs... - NDTV

Booking a jab should be ‘as easy as booking a cab’, NHS chief says – The Independent

December 13, 2023

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails

Booking a jab should be as easy as booking a cab, the head of the NHS has said as part of a drive to push up vaccination rates.

Amanda Pritchard set out plans to extend the NHS app so people can get easier access to their vaccine record, book convenient appointments and keep track of their childrens vaccinations.

The NHS has launched a new vaccines strategy to urge people to get jabs in light of a 10-year decline in some immunisations, with particular concern over the measles, mumps and rubella (MMR) vaccine.

MMR jab in 2022/23" data-source="">

In 2022/23, 92.5% of five-year-old children received their first dose of the MMR jab the lowest level since 2010/11.

And only 84.5% of five-year-olds received two doses also the lowest proportion since 2010/11.

The new strategy will set out the need for an easy and convenient front door to vaccines and will plan for tackling regional variations in uptake, including overcoming the hesitancy some parents feel regarding jabs for their children.

The strategy is expected to say that MMR vaccination rates across local authority areas in England vary by as much as 22% and will point to how building trust in local communities could help drive down this variation.

Booking invitations and reminders could be made more personalised and accessible, the strategy will say, while one-stop shops where people can get jabs at the same time as blood pressure checks will be set up.

In 2025/26, the ambition is to use the NHS app to streamline access to a wider group of vaccinations for adults, children and young people, including jab invitations, in-app bookings, appointment notifications and access to vaccination records.

User-experience will also be improved through people being able to access same-day cancellations and make group bookings.

Through the NHS app, well make sure booking a jab can be as easy as booking a cab so millions more people can get vaccinated

Amanda Pritchard, NHS

The strategy is expected to focus on targeting hard-to-reach groups, who are already being seen through initiatives such as school vaccination teams attending parents evenings or pop-up family clinics in childrens hospitals.

Booking and receiving more than one vaccine in a single visit as is already happening for Covid and flu jabs will become easier, while walk-in services will also be more widely publicised.

More use of jab stops in places such as shopping centres will also be encouraged.

Ms Pritchard said: Through the NHS app, well make sure booking a jab can be as easy as booking a cab so millions more people can get vaccinated.

Users will be able to access their full vaccine status in a matter of seconds and book jabs with a simple swipe and tap.

And well continue to expand the amazing work of NHS staff, volunteers and partners to introduce even more pop-up sites in the heart of our local communities.

We want to see even more people supported to take up the offer of lifesaving vaccinations its the best way to protect you and those around you from illnesses which can be fatal, so please do come forward if invited, and if youre unsure or have questions, the NHS is here to help

Steve Russell, NHS England

So, when you are invited for any of your vaccinations, please do book without delay it could be lifesaving.

Steve Russell, national director for vaccinations and screening for NHS England, said: Vaccination is one of the best ways to boost public health, second only to clean water, which is why our vaccine strategy takes vital lessons from our world-leading NHS Covid-19 vaccine programme and the extraordinary efforts of local teams who found innovative ways to reach people during the pandemic and saved thousands of lives.

This includes taking vaccines into the heart of communities where we see lower uptake rates, so offering vaccines at pop-up clinics and health hubs in shopping centres, and local schools teams going into parents evenings to address barriers to people consenting to their childs vaccinations.

We want to see even more people supported to take up the offer of lifesaving vaccinations its the best way to protect you and those around you from illnesses which can be fatal, so please do come forward if invited, and if youre unsure or have questions, the NHS is here to help.

Health minister Maria Caulfield said: To ensure as many people get vaccinated as possible, we need to make sure the programme fits around peoples lives.

More than 33 million people are currently signed up to the NHS app.

Read the rest here:

Booking a jab should be 'as easy as booking a cab', NHS chief says - The Independent

There’s more work to do to close the racial gap in COVID-19, flu vaccination – Chicago Sun-Times

December 13, 2023

As the holidays approach, so does the risk of COVID and flu infection.

Unfortunately, only16% of adultsin the United States have received a COVID-19 booster vaccine as of last month, andonly 38.7%have received this years flu vaccination.

The statistics for Black Americans are even more alarming, with only 10.7% having received the COVID booster and 33.5% the updated flu vaccine.

The racial gap has drastically narrowed since the first COVID vaccines became available nearly two years ago, when the vaccination rate for Black Americans washalfthat of white people in the United States.Still, by May of this year, only 50% of Black Americans had received at least one dose of the COVID vaccine, compared with 55% of White Americans.

In Chicago, city data show that only 6.1% of Black residents and 5.4% of Latinos, compared with 17.7% of whites and 12.2% of Asians, are up-to-date on their COVID-19 vaccination series.

Vaccine equity has been a priority of the National Urban League and our nationwide network of affiliates since the first rollout.In response to the early drastic disparity, we commissioned apoll, in partnership with the Alliance of National Psychological Associations for Racial and Ethnic Equity, examining attitudes toward vaccination.

According to our findings, access, not hesitancy, was the primary driver of racial disparity in vaccination rates, contrary to the blame-the-victim media narrative that prevailed at the time.

Among those who were hesitant, the primary barrier was concerns about vaccine safety, much of it stemming from misinformation and conspiracy theories. We immediately recognized our challenge not only to advocate for equitable access to vaccines, but also to employ trusted messengers such as public health professionals, community leaders, and neighbors to address concerns about the vaccines safety.

I was proud to join a group of trusted clergy in my own communitywho received the vaccine publiclyin an effort to build trust.

Thats why we partnered with the Centers for Disease Control and Prevention on theALL INcampaign, helping to inform Black Americans about the vaccines and to empowered them to make the best decisions for them, their family and their communities.

We enlisted our affiliates, including theChicago Urban League, to use proven electoral outreach strategies, such as phone banking, neighborhood canvassing, or hosting telephone town halls, to engage Black and African American communities directly about vaccines. We trained trusted messengers to participate in text bank campaigns to inform communities on the recommended fall vaccine schedule, knocked on doors to extend invitations to local vaccine events, and offered their expertise to answer questions about the vaccines during local telephone town halls.

Thanks to the efforts of the National Urban League and other racial justice groups, vaccine hesitancy among Black Americans has declined.In fact, the primary the primary predictor of vaccine hesitancy is not race, butpolitical party affiliation, according to a survey byKFF.

Overcoming vaccine hesitancy is just part of the battle. The structural and institutional racial inequities the National Urban League exposed in our State of Black America report, Unmasked still persist.While the Affordable Care Act has drastically expanded health insurance coverage and narrowed the racial gap, 10% of Black Americansremain uninsured,compared with 6.7% of whites. Black Americans are 50% more likelyto go without health caredue to cost.Black children are nearly twice as likely to rely on emergency rooms as their only source of health care.

The most recent National Urban LeagueEquality Index, a calculation of the economic and social status of Black Americans relative to whites, was 84.0% for health.Keeping up to date on vaccinations, especially during this holiday season, is one way we can work to bring the Index to 100%

Marc H. Morial is president and CEO of the National Urban League. He served as mayor of New Orleans from 1994 to 2002 and is a graduate of the University of Pennsylvania and the Georgetown University Law Center.

The Sun-Times welcomes letters to the editor and op-eds.See our guidelines.

See more here:

There's more work to do to close the racial gap in COVID-19, flu vaccination - Chicago Sun-Times

Scientists find new, better way to develop vaccines – Medical Xpress

December 13, 2023

This article has been reviewed according to ScienceX's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

close

A new paper in Biology Methods & Protocols indicates that researchers in Germany have developed a new system to display epitopes in mammal cells for immunization studies. They believe that this method can help scientists greatly in immunization efforts.

Promoting blood cells to produce antibodies against a specific viral protein is an important step in developing vaccines for human use. This can be challenging for researchers because whether the subjects develop antibodies depends on how scientists design and administer antigens, which are parts of the virus they're administering to test the effectiveness of the vaccine.

One very important aspect of virus research is how to express and purify the antigen for vaccination. Animals immunized with prepared antigens produce specific antibodies against the antigen. But scientists have to isolate the antigen to ensure that they develop the vaccine to target the specific disease they wish to combat.

Once researchers purify the antigen, they can develop vaccines that lead subjects to produce the desired antibodies. But this isolation is especially time-consuming when attempting to develop lab-produced antigens as a virus often mutates rapidly. It can take several weeks for scientists to develop the right antigens.

Here scientists developed a new method to induce target-specific immune responses. By fusing antigen proteins into a tetraspanin-derived anchor membrane-bound protein, the researchers created fusion proteins that are displayed predominantly on the surface of human cells.

The exposition of proteins on the surface by a carrier protein induces the production of antibodies directed against the appropriate, relevant, antigens. Of additional advantage is that these antigens have the same conformation and modifications as the corresponding proteins in the virus because they are made by cells similar to that in the human body, which the virus infects naturally.

This new display technology could be a potentially much more reliable immunization technique. In the study here the researchers were able to induce antibodies against different proteins with a focus on the receptor-binding domain of SARS-CoV-2, the virus that causes Coronavirus Disease 2019 (COVID-19). The developed anchor protein allows scientists to target a specific disease for immunization purposes without the need to purify the antigen. The researchers are convinced that this technique can speed up the immunization process enormously.

"This work is based on the receptor binding domain of SARS-CoV-2 and is only the beginning of a very interesting immunization technique," said Daniel Ivanusic, one of the paper's authors. "The most challenging, significant, and exciting application for us employing the tANCHOR technology is to induce neutralizing antibodies against HIV-1. I think this will be great."

More information: Hubert Bernauer et al, tANCHOR fast and cost-effective cell-based immunization approach with focus on the receptor-binding domain of SARS-CoV-2, Biology Methods & Protocols (2023). DOI: 10.1093/biomethods/bpad030

Read more:

Scientists find new, better way to develop vaccines - Medical Xpress

The Value, Science, & Policies Surrounding Vaccines – RealClearHealth

December 13, 2023

The pandemic gave the country opportunities to make health care more affordable and accessible with a public-private partnership the most demonstrably successful pandemic program. The threat of the coronavirus diminished for many Americans thanks to the COVID vaccines.

What have we learned from the experience? What does the future look like for vaccine science and accessibility? What can innovators and policymakers do today to advance medical progress? Join us Tuesday, December 12, 2023, for a conversation on the value, science, and policies surrounding vaccines. A conversation around the value proposition of vaccines in older adults, the important role preventative health care will play in sustaining the viability of our nations healthcare system, and the policies that both sides of the political aisle can support now to reinforce better health outcomes moving forward.

Panelists:

Eric Hargan, Founder and CEO, The Hargan Group

Eric was Deputy Secretary of the Department of Health and Human Services (HHS) from 2017 to 2021, as well as Acting Secretary in 2017-2018. In addition to serving on the Board of Operation Warp Speed, Eric oversaw the set-up and launch of the Provider Relief Fund, the Kidney Health Initiative, and worked with multiple public and private sector entities to facilitate efforts across the entire endeavor in developing vaccines and therapeutics.

Kirsten Axelsen, nonresident fellow at the American Enterprise Institute (AEI)

She focuses primarily on domestic and international pharmaceutical policy. In addition to her AEI work, Ms. Axelsen is a consultant to biopharmaceutical and other life science companies. Before joining AEI, Ms. Axelsen worked for over 20 years in the biopharmaceutical industry, both in-house and as a consultant. As vice president for strategy and new business assessment in Pfizers Innovative Health and Essential Health units, she oversaw business-development evaluations in the fields of rare disease, oncology, inflammation, immunology, and primary care.

Randall Lutter, Ph.D., senior fellow at the Manhattan Institute

His research focuses on pharmaceutical markets and policy, medical innovation, and regulation. As senior science and regulatory advisor in the Office of the Commissioner at the U.S. Food and Drug Administration (FDA) from 2017 to 2020. Dr. Lutter previously served at FDA from 2003 to 2009, first as chief economist and later as deputy commissioner for policy.

Henry I. Miller, a physician and molecular biologist

He is the Glenn Swogger Distinguished Fellow at the American Council on Science and Health. He was the founding director of the FDA's Office of Biotechnology. From 1994 until 2018, Dr. Miller was the Robert Wesson Fellow in Scientific Philosophy and Public Policy at Stanford University's Hoover Institution.

Originally posted here:

The Value, Science, & Policies Surrounding Vaccines - RealClearHealth

Patients can interrupt immune-suppressing medicines to boost immunity provided by COVID-19 booster, finds study – Medical Xpress

December 13, 2023

This article has been reviewed according to ScienceX's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

close

A major clinical trial, led by experts at the University of Nottingham, has shown that people with inflammatory conditions are able to improve the antibody response from a COVID-19 booster vaccination by interrupting their treatment for two weeks immediately after having the vaccine.

The antibody response to the jab was doubled at four weeks, and one and a half times greater at 26 weeks, when compared to those who continued with their treatment as usual. The improved antibody response lasted for six months.

Patients who interrupted treatment reported experiencing more flare-ups of their inflammatory conditions in the next few weeks, but most flares were self-managed, and most didn't need help from a health care provider.

The interim findings of the Vaccine Response On Off Methotrexate (VROOM) trial (which was restricted to 250 patients and followed up for 12 weeks) were previously published in Lancet Respiratory Medicine. They have already influenced the British and American clinical guidelines.

The full trial findings from 383 participants, which are published in Lancet Rheumatology, show that the improved protection lasts for six months. The full trial also shows that the blood from people who stopped methotrexate was also more efficient at killing the Wuhan strain and the omicron BA.1 variant. It also shows that when the six-month follow-up period was considered, there was no excess risk of disease flares in patients who suspended their treatment immediately after a COVID-19 booster vaccination.

These findings will be useful for national immunization advisory committees, and other specialist societies formulating recommendations on the timing of vaccination in those treated with or starting medicines that turn down the immune system.

The VROOM trial recruited patients with a range of inflammatory conditions treated with methotrexate. Methotrexate is the most used immune-suppressing drug, with around 1.3 million people in the UK prescribed this medicine for inflammatory conditions such as rheumatoid arthritis, and skin conditions such as psoriasis.

Many of them were among the 2.2 million clinically extremely vulnerable people advised to shield during the first phase of the COVID-19 pandemic, depending on specialist advice and on their risk factors.

While methotrexate is effective at controlling these conditions and has emerged as first-line therapy for many illnesses, it reduces the body's ability to fight infections and the ability to generate a robust response to flu and pneumonia vaccines, including those against COVID-19.

Chief Investigator, Professor Abhishek at the University of Nottingham and Honorary Consultant Rheumatologist at Nottingham University Hospitals NHS Trust, said, "COVID-19 has not gone away, and with the emergence of new variants, and vaccine hesitancy among patients, it is important to optimize durable protection in people who are susceptible to COVID-19. Evidence from our trial will help patients and clinicians make informed choices about the risks and benefits of interrupting methotrexate treatment around the time of vaccination against COVID-19."

Professor Danny McAuley, Scientific Director for NIHR Programs, said, "As winter approaches, millions of people with compromised immune systems are still vulnerable to becoming unwell from COVID-19, despite the disease being less prevalent than it once was.

"This important research provides even more high quality evidence that by managing medicines in relation to vaccinations we can keep patients healthier while reducing pressure on the NHS."

The study was carried out in collaboration with colleagues from the University of Manchester, Imperial College London, the University of Oxford, Queen Mary University London, UK Health Security Agency (formerly Public Health England) and participating NHS hospitals. The study was managed by the Oxford Clinical Trials Research Unit (OCTRU).

More information: Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immunemediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial, The Lancet Rheumatology (2023). DOI: 10.1016/S2665-9913(23)00298-9

Journal information: Lancet Respiratory Medicine , The Lancet Rheumatology

Continue reading here:

Patients can interrupt immune-suppressing medicines to boost immunity provided by COVID-19 booster, finds study - Medical Xpress

Page 131«..1020..130131132133..140150..»